# GCC Rapid Diagnostics Market > GCC Rapid Diagnostics Market Research Report By Application (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.8% - **2024:** $ 786.07 Million - **2025:** $ 855.25 Million - **2035:** $ 1,988 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Quidel Corporation (US) **Report ID:** MRFR/MED/43667-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-rapid-diagnostics-market-45347 --- ## Market Summary ## **GCC Rapid Diagnostics Market Overview** As per MRFR analysis, the GCC Rapid Diagnostics Market Size was estimated at 722.5 (USD Million) in 2023.The GCC Rapid Diagnostics Market Industry is expected to grow from 785.0(USD Million) in 2024 to 1,961.0 (USD Million) by 2035. The GCC Rapid Diagnostics Market CAGR (growth rate) is expected to be around 8.679% during the forecast period (2025 - 2035). **Key GCC Rapid Diagnostics Market Trends Highlighted** An increased focus on modern medicine is driving significant trends within the GCC Rapid Diagnostics Market. The region’s governments are heavily funding healthcare reforms to improve health and strengthen disease readiness. This shift resulted in a rapid increase in the use of rapid diagnostic tests in various areas, including infectious and chronic disease management. Non-communicable diseases coupled with the ever-present threat of infectious disease outbreaks are leading to an increase in the need for fast, accurate, and accessible diagnostic tools. The GCC market is also opening up due to new technologies like point-of-care testing and home-testing kits. These innovations reinforce the region's digital health and telemedicine push, but they also improve patient convenience. In addition, rapid diagnostic device imports could be replaced with local government supported manufacturing, which would boost the regional economy and decrease reliance on imports. There is also a noticeable trend in increasing consumer concern about health and preventative care, which in turn leads to increased demand for rapid testing options. Most of this demand stems from the COVID-19 pandemic, which showed how crucial quick diagnostic results are for controlling the public’s health effectively. The market for rapid diagnostics in the Gulf Cooperation Council region is being externally stimulated by the use of technology and public health awareness, creating positive opportunities for innovations and advancements in the region. **GCC Rapid Diagnostics Market Drivers** **Increasing Burden of Infectious Diseases** The GCC Rapid Diagnostics Market Industry is set to experience substantial growth due to the increasing prevalence of infectious diseases in the region. According to the WHO, the GCC countries have witnessed a rise in infectious disease cases, with a special emphasis on rising respiratory illnesses. The Saudi Arabian Ministry of Health reported a 25% increase in respiratory infections in the last five years, primarily driven by factors like urbanization and climate change.This rising burden necessitates rapid and accurate diagnostics, paving the way for advancements in rapid testing technologies. Institutions such as the UAE's Dubai Health Authority are actively promoting rapid diagnostic solutions to enhance healthcare delivery, thus fueling market growth. **Government Initiatives and Regulations** Governments in the GCC region are proactively investing in healthcare systems, including the expansion of rapid diagnostics. The UAE's Vision 2021 and Saudi Arabia's Vision 2030 aim to improve healthcare services, with a strong focus on preventive health measures. These initiatives encourage the adoption of modern diagnostic technologies. Recent policy changes have allocated significant funding towards healthcare infrastructure, which includes diagnostic facilities.This investment not only aids disease prevention but fosters a conducive environment for the GCC Rapid Diagnostics Market Industry to thrive. **Technological Advancements in Diagnostics** The rapid advancements in diagnostic technologies, particularly point-of-care testing and molecular diagnostics, are major drivers for the GCC Rapid Diagnostics Market. The increasing integration of artificial intelligence and machine learning in diagnostics allows for quicker and more reliable test results. Research from the Ministry of Health in Bahrain indicates a 30% faster test result turnaround time with modern diagnostic tools compared to traditional methods.This speed is crucial in emergency medical situations, especially given the growing awareness of timely clinical decision-making. Companies like Abbott and Roche are at the forefront of this technological evolution, providing innovative products that cater to the unique healthcare demands of the GCC region. **Rising Awareness of Preventive Healthcare** The GCC populace is becoming increasingly aware of the importance of preventive healthcare, driven by initiatives from health ministries and health campaigns. Recent studies suggest that over 60% of the population in countries like Qatar and Kuwait are actively participating in health screenings and preventive measures, reflecting a cultural shift towards early diagnostics. This trend is supported by local organizations promoting regular health check-ups and awareness programs centered on infectious and chronic diseases.As awareness rises, the demand for rapid diagnostic solutions will concurrently escalate, further propelling the GCC Rapid Diagnostics Market Industry forward. **GCC Rapid Diagnostics Market Segment Insights** **Rapid Diagnostics Market Application Insights** The GCC Rapid Diagnostics Market reveals a robust expansion in the Application segment, driven by advancements in healthcare technology and increasing demand for swift diagnostic results across various medical fields. Blood Glucose Testing has become crucial in diabetes management, particularly in GCC countries where lifestyle diseases are on the rise, showcasing a pressing need for timely glucose monitoring. Infectious Disease Testing, particularly in the wake of the COVID-19 pandemic, has gained significant traction, underscoring the importance of rapid results in controlling outbreaks and ensuring public health safety.Cardiometabolic Testing has emerged as an essential tool for assessing risks associated with cardiovascular diseases, increasingly recognized within the healthcare systems in the region, supporting initiatives aimed at improving heart health awareness.  Pregnancy Fertility Testing are also gaining momentum, driven by rising awareness regarding reproductive health and family planning, demonstrating a clear shift in social attitudes towards health ownership. Fecal Occult Blood Testing provides vital early detection of colorectal conditions, enhancing overall preventive care strategies in the GCC, which is gaining governmental and institutional backing.Coagulation Testing remains a fundamental aspect of managing anticoagulation therapy, vital for patient safety in a region that is witnessing growing incidences of thromboembolic disorders.  Toxicology Testing plays a significant role in personal safety and law enforcement, becoming increasingly relevant with strict regulations on substance abuse and the need for workplace safety measures. The integration of these testing methodologies into routine clinical practice is based on the overarching goal of improving patient outcomes and enhancing healthcare system efficiency across the GCC.Each of these applications is supported by increasing investments in healthcare infrastructure and public health initiatives, positioning the GCC as a dynamic player in the rapid diagnostics landscape. **Rapid Diagnostics Market Product Type Insights** The GCC Rapid Diagnostics Market has witnessed substantial growth in its Product Type segment, particularly through Over the Counter (OTC) Kits and Professional Kits, which are critical in enhancing accessible healthcare solutions across the region. OTC Kits, which can be easily obtained without a prescription, empower consumers to manage their health independently, making them increasingly popular amidst the rising emphasis on preventive healthcare. In contrast, Professional Kits are primarily utilized by healthcare practitioners, providing more accurate testing and aiding in timely diagnoses in clinical settings.The growing prevalence of chronic diseases and infectious outbreaks necessitates effective diagnostic tools, placing significant importance on these kits.  Furthermore, with advancements in technology and increasing public awareness regarding health issues, both product types are expected to complement each other, catering to diverse consumer needs. As the healthcare landscape continues to evolve in the GCC region, the demand for both OTC and Professional Kits reflects a broader trend towards quicker, more efficient diagnostic solutions, thereby driving the overall market growth.The GCC's strategic investments in healthcare infrastructure further bolster the positioning of these product types, ensuring their pivotal role in future healthcare delivery. **GCC Rapid Diagnostics Market Key Players and Competitive Insights** The GCC Rapid Diagnostics Market has shown significant dynamics influenced by evolving healthcare needs, technological advancements, and regulatory frameworks. The market is characterized by a diverse array of stakeholders, including manufacturers, distributors, and healthcare providers, all vying for a share of this burgeoning sector. Key factors driving competition include innovation in product offerings, advancements in testing technologies, and strategic partnerships. The market is further heightened by the push for early disease detection and increased focus on preventive healthcare measures, resulting in a growing demand for rapid diagnostic tests across various medical conditions.  Companies are positioning themselves strategically to address the unique healthcare challenges of the GCC region, thereby shaping a competitive landscape that is dynamic and multifaceted.The Binding Site Group has established a robust presence in the GCC Rapid Diagnostics Market through its innovative product offerings and strong relationships with healthcare providers. With a focus on specialized diagnostics, the company has leveraged its expertise to develop tests that address pressing health issues in the region. It has built a reputation for reliability and accuracy, which resonates well with local healthcare demands. The Binding Site Group’s strength lies in its commitment to research and development, consistently rolling out cutting-edge diagnostic solutions that cater specifically to the needs of healthcare professionals in the GCC. This strategy positions the company favorably as a trusted partner in enhancing patient care, thus helping it to maintain a competitive edge.PerkinElmer has made significant strides in the GCC Rapid Diagnostics Market by offering a comprehensive portfolio of products and services that cater to various aspects of rapid diagnostics. The company’s presence in the region is marked by its focus on delivering high-quality diagnostic solutions and expanding its reach through strategic partnerships and collaborations with local healthcare entities.  PerkinElmer’s key products include testing solutions for infectious diseases, metabolic disorders, and other critical health conditions, allowing for timely diagnosis and treatment. The Gulf Cooperation Council region benefits from PerkinElmer’s established strengths in technological innovation and application-specific expertise. Recent mergers and acquisitions have further fortified the company's capabilities, enabling it to expand its service offerings and enhance customer satisfaction, ultimately reinforcing its position in the rapidly evolving market landscape in the GCC. **Key Companies in the GCC Rapid Diagnostics Market Include:** - The Binding Site Group - PerkinElmer - Roche Diagnostics - Quidel Corporation - Hologic - BioMérieux - Thermo Fisher Scientific - Ortho Clinical Diagnostics - Danaher Corporation - Siemens Healthineers - Abbott Laboratories - Cepheid - Fujifilm - ZyGene - BD **GCC Rapid Diagnostics Market Industry Developments** The GCC Rapid Diagnostics Market has seen significant growth recently, driven by an increased focus on healthcare and advancements in diagnostic technology. In September 2023, The Binding Site Group introduced new assays that are expected to enhance the accuracy of immunodiagnostic testing across the region.  Meanwhile, PerkinElmer expanded its operations by opening a state-of-the-art diagnostics facility in the UAE, aimed at boosting local manufacturing capabilities. Roche Diagnostics has been actively involved in various healthcare initiatives, supporting public health responses to COVID-19, thus strengthening its presence in the GCC.  Notably, in June 2023, Quidel Corporation acquired a diagnostic company to expand its product portfolio, particularly in emerging markets. Hologic reinforced its market position through collaborations with regional governments to supply advanced molecular testing equipment. A growing emphasis on preventive healthcare and digital health innovations is driving the rapid diagnostics landscape, with prominent players like Abbott Laboratories and Siemens Healthineers investing heavily in RD.  The market is projected to thrive further as governments in the GCC region focus on enhancing healthcare infrastructure, thus increasing demand for rapid diagnostic solutions. **GCC Rapid Diagnostics Market Segmentation Insights** - **Rapid Diagnostics Market Application Outlook** - Blood Glucose Testing - Infectious Disease Testing - Cardiometabolic Testing - PregnancyFertility Testing - Fecal Occult Blood Testing - Coagulation Testing - Toxicology Testing - **Rapid Diagnostics Market Product Type Outlook** - Over the Counter (OTC) Kits - Professional Kits ## Market Drivers ### Government Initiatives and Funding Government support plays a crucial role in the growth of the rapid diagnostics market. In the GCC, various initiatives aimed at enhancing healthcare infrastructure and accessibility are being implemented. Increased funding for healthcare projects and research is likely to bolster the development of rapid diagnostic technologies. For example, several GCC countries have launched national health strategies that prioritize the integration of advanced diagnostic tools into healthcare systems. This governmental backing not only facilitates innovation but also encourages public-private partnerships, which are essential for advancing the rapid diagnostics market. As a result, the market is expected to expand, driven by enhanced resources and strategic initiatives. ### Rising Prevalence of Chronic Diseases The increasing incidence of chronic diseases in the GCC region is a pivotal driver for the rapid diagnostics market. Conditions such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more prevalent, necessitating timely and accurate diagnostic solutions. According to recent health statistics, the prevalence of diabetes in the GCC has reached alarming levels, with estimates suggesting that around 20% of the adult population is affected. This surge in chronic conditions drives demand for rapid diagnostic tools that can facilitate early detection and management, thereby enhancing patient outcomes. The rapid diagnostics market is likely to benefit from this trend, as healthcare providers seek efficient solutions to address the growing burden of chronic diseases. ### Increased Focus on Preventive Healthcare There is a notable shift towards preventive healthcare in the GCC, which significantly influences the rapid diagnostics market. Governments and health organizations are increasingly promoting health screenings and early detection programs to mitigate the impact of diseases. This proactive approach is reflected in various national health initiatives aimed at reducing healthcare costs and improving population health. The rapid diagnostics market is poised to thrive as more individuals seek out diagnostic tests that can identify health issues before they escalate. The emphasis on preventive measures is expected to drive innovation and adoption of rapid diagnostic technologies, ultimately leading to improved health outcomes across the region. ### Growing Demand for Home Healthcare Solutions The demand for home healthcare solutions is on the rise in the GCC, significantly impacting the rapid diagnostics market. As patients increasingly prefer receiving care in the comfort of their homes, there is a corresponding need for diagnostic tools that can be used outside traditional clinical settings. This trend is particularly relevant for chronic disease management, where regular monitoring is essential. The rapid diagnostics market is likely to see a surge in the development of user-friendly, portable diagnostic devices that cater to this demand. The convenience and accessibility of home healthcare solutions are expected to drive growth in the market, as they empower patients to take charge of their health. ### Technological Innovations in Diagnostic Tools Technological advancements are reshaping the landscape of the rapid diagnostics market. Innovations such as point-of-care testing, mobile health applications, and advanced biomarker detection methods are enhancing the speed and accuracy of diagnostics. The GCC region is witnessing a surge in the adoption of these technologies, driven by the need for rapid results in clinical settings. For instance, the market for point-of-care testing devices is projected to grow at a CAGR of over 10% in the coming years. This growth indicates a strong demand for rapid diagnostics market solutions that can deliver timely results, thereby improving patient management and treatment outcomes. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) is projected to grow at 8.8% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for point-of-care testing, and rising healthcare expenditure. **New opportunities:** - Development of mobile diagnostic units for remote areas - Integration of AI in diagnostic tools for enhanced accuracy - Expansion of telehealth services incorporating rapid testing solutions By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Over-the-Counter (OTC) Kits (Largest) vs. Professional Kits (Fastest-Growing) The GCC rapid diagnostics market exhibits a diverse landscape in its product offerings, with Over-the-Counter (OTC) Kits leading the segment by capturing a significant share. These kits have become increasingly popular among consumers seeking convenient and quick testing solutions at home, which has drastically enhanced their visibility and availability. In contrast, Professional Kits are gaining traction among healthcare providers and laboratories, emphasizing the move towards advanced diagnostic solutions. Growth trends in the product segment indicate a robust increase in demand for both Over-the-Counter (OTC) and Professional Kits. The surge in health awareness, coupled with an increase in chronic disease prevalence, is fueling this growth. The ease of access to OTC Kits is revolutionizing self-diagnosis, while technological advancements in Professional Kits are enhancing accuracy and efficiency, catering to a broader range of diagnostic needs. Over-the-Counter (OTC) Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter (OTC) Kits hold a dominant position in this segment due to their convenience, affordability, and growing acceptance among consumers. These kits enable individuals to conduct tests without the need for a healthcare professional, fostering autonomy in health management. Meanwhile, Professional Kits are emerging as a critical component for clinical settings, characterized by their precision and reliability. Health institutions are increasingly adopting these kits to streamline testing processes, influenced by technological innovations that improve diagnostic accuracy. Both segments are witnessing enhancements in design and functionality, aimed at improving user experience and outcomes. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) The GCC rapid diagnostics market exhibits a diverse segment distribution, with Blood Glucose Testing leading due to its vital role in diabetes management. This segment holds a significant share, driven by the increasing prevalence of diabetes and awareness about blood glucose monitoring. Infectious Disease Testing, while smaller, is fast gaining traction owing to rising global health concerns and technological advancements in rapid test kits. Growth trends in the GCC rapid diagnostics market are propelled by several factors, including technological innovations, an increasing emphasis on point-of-care testing, and expanded healthcare access. Additionally, the rising incidence of infectious diseases fuels demand for diagnostics in areas like sexually transmitted infections and COVID-19. This dynamic landscape indicates a robust growth trajectory for these segments over the coming years. Blood Glucose Testing: Dominant vs. Infectious Disease Testing: Emerging Blood Glucose Testing remains a dominant force in the GCC rapid diagnostics market, primarily due to the escalating diabetes epidemic that necessitates effective management solutions. This segment is characterized by a broad range of devices and technologies, ensuring user-friendly monitoring options. In contrast, Infectious Disease Testing is emerging rapidly, driven by increasing public health awareness and the need for quick, accurate diagnoses of communicable diseases. The latter segment benefits from innovations in rapid testing methodologies and the necessity for timely health interventions, making it a pivotal area for expansion in the market. ### Rapid Diagnostics Market Product Type Insights Rapid Diagnostics Market Product Type Insights The GCC Rapid Diagnostics Market has witnessed substantial growth in its Product Type segment, particularly through Over the Counter (OTC) Kits and Professional Kits, which are critical in enhancing accessible healthcare solutions across the region. OTC Kits, which can be easily obtained without a prescription, empower consumers to manage their health independently, making them increasingly popular amidst the rising emphasis on preventive healthcare. In contrast, Professional Kits are primarily utilized by healthcare practitioners, providing more accurate testing and aiding in timely diagnoses in clinical settings.The growing prevalence of chronic diseases and infectious outbreaks necessitates effective diagnostic tools, placing significant importance on these kits.  Furthermore, with advancements in technology and increasing public awareness regarding health issues, both product types are expected to complement each other, catering to diverse consumer needs. As the healthcare landscape continues to evolve in the GCC region, the demand for both OTC and Professional Kits reflects a broader trend towards quicker, more efficient diagnostic solutions, thereby driving the overall market growth.The GCC's strategic investments in healthcare infrastructure further bolster the positioning of these product types, ensuring their pivotal role in future healthcare delivery. ## Competitive Benchmarking The rapid diagnostics market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for timely and accurate diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which allows for rapid results in various settings. Roche Diagnostics (CH) emphasizes its strong portfolio in molecular diagnostics, leveraging its expertise to expand into emerging markets. Siemens Healthineers (DE) is investing heavily in digital transformation, integrating AI and data analytics into its diagnostic solutions, thereby enhancing operational efficiency and customer engagement. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players holding substantial market shares while also facing competition from smaller, innovative firms. This fragmentation allows for a diverse range of products and services, catering to various customer needs and preferences. In October Roche Diagnostics (CH) announced a strategic partnership with a leading telehealth provider to integrate its diagnostic solutions into remote healthcare services. This move is significant as it positions Roche to capitalize on the growing trend of telemedicine, enabling faster diagnostics and improved patient outcomes. By aligning with telehealth, Roche is likely to enhance its market reach and reinforce its commitment to accessible healthcare. In September Siemens Healthineers (DE) launched a new AI-driven diagnostic platform aimed at streamlining laboratory workflows. This platform is designed to reduce turnaround times and improve accuracy in test results. The introduction of this technology underscores Siemens' focus on digitalization and its potential to transform laboratory operations, thereby enhancing its competitive edge in the market. In November Abbott Laboratories (US) expanded its product line with the introduction of a rapid diagnostic test for infectious diseases, which is expected to significantly improve testing capabilities in resource-limited settings. This expansion not only reflects Abbott's commitment to innovation but also its strategic intent to address global health challenges, potentially increasing its market share in underserved regions. As of November current trends in the rapid diagnostics market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage complementary strengths and enhance their offerings. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine market dynamics, compelling companies to invest in R&D and strategic partnerships to maintain a competitive advantage. ## Recent News & Developments The GCC Rapid Diagnostics Market has seen significant growth recently, driven by an increased focus on healthcare and advancements in diagnostic technology. In September 2023, The Binding Site Group introduced new assays that are expected to enhance the accuracy of immunodiagnostic testing across the region.  Meanwhile, PerkinElmer expanded its operations by opening a state-of-the-art diagnostics facility in the UAE, aimed at boosting local manufacturing capabilities. Roche Diagnostics has been actively involved in various healthcare initiatives, supporting public health responses to COVID-19, thus strengthening its presence in the GCC.  Notably, in June 2023, Quidel Corporation acquired a diagnostic company to expand its product portfolio, particularly in emerging markets. Hologic reinforced its market position through collaborations with regional governments to supply advanced molecular testing equipment. A growing emphasis on preventive healthcare and digital health innovations is driving the rapid diagnostics landscape, with prominent players like Abbott Laboratories and Siemens Healthineers investing heavily in RD.  The market is projected to thrive further as governments in the GCC region focus on enhancing healthcare infrastructure, thus increasing demand for rapid diagnostic solutions. ## Report Scope | MARKET SIZE 2024 | 786.07(USD Million) | | --- | --- | | MARKET SIZE 2025 | 855.25(USD Million) | | MARKET SIZE 2035 | 1988.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Quidel Corporation (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Integration of advanced technologies enhances accuracy and speed in the rapid diagnostics market. | | Key Market Dynamics | Technological advancements drive rapid diagnostics adoption, enhancing healthcare efficiency and patient outcomes in the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the market valuation of the GCC rapid diagnostics market in 2024?** A: The market valuation was $786.07 Million in 2024. **Q: What is the projected market valuation for the GCC rapid diagnostics market by 2035?** A: The projected market valuation for 2035 is $1988.0 Million. **Q: What is the expected CAGR for the GCC rapid diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 8.8%. **Q: Which companies are considered key players in the GCC rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What were the sales figures for Over-the-Counter (OTC) Kits in the GCC rapid diagnostics market?** A: Sales for Over-the-Counter (OTC) Kits were $315.0 Million in 2024 and are projected to reach $792.0 Million by 2035. **Q: How did the Professional Kits segment perform in the GCC rapid diagnostics market?** A: The Professional Kits segment had a valuation of $471.07 Million in 2024, with projections of $1196.0 Million by 2035. **Q: What applications are included in the GCC rapid diagnostics market?** A: Applications include Blood Glucose Testing, Infectious Disease Testing, and Cardiometabolic Testing, among others. **Q: What was the valuation for Infectious Disease Testing in 2024?** A: Infectious Disease Testing was valued at $157.22 Million in 2024. **Q: What is the projected valuation for Blood Glucose Testing by 2035?** A: The projected valuation for Blood Glucose Testing by 2035 is $198.0 Million. **Q: How does the growth of the GCC rapid diagnostics market compare to other regions?** A: While specific comparisons to other regions are not provided, the GCC market's projected growth appears robust with a CAGR of 8.8%. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-rapid-diagnostics-market-45347*